Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hoyle M"" wg kryterium: Autor


Tytuł :
Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation.
Autorzy :
Varley-Campbell, J.
Mújica-Mota, R.
Coelho, H.
Ocean, N.
Barnish, M.
Packman, D.
Dodman, S.
Cooper, C.
Snowsill, T.
Kay, T.
Liversedge, N.
Parr, M.
Knight, L.
Hyde, C.
Shennan, A.
Hoyle, M.
Pokaż więcej
Temat :
FETAL FIBRONECTIN
TEST ACCURACY
PLACENTAL ALPHA MACROGLOBULIN-1
PHOSPHORYLATED INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
Research Article
R855-855.5
PH(IGFBP-1)
ACTIM PARTUS
PAMG-1
PARTOSURE
Medical technology
Źródło :
Health Technology Assessment, 23 (13) pp. 1-226. (2019)
Health Technology Assessment, Vol 23, Iss 13 (2019)
Opis pliku :
text
Tytuł :
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Autorzy :
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Griffin E; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lucherini S; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Talens-Bou J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Sherriff D; Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK.
Napier M; Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Ramage J; Neuroendocrine Tumour Service, King's College Hospital NHS Foundation Trust, London, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2018 Sep; Vol. 22 (49), pp. 1-326.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Everolimus/*therapeutic use
Neuroendocrine Tumors/*drug therapy
Octreotide/*analogs & derivatives
Organometallic Compounds/*therapeutic use
Radioisotopes/*therapeutic use
Sunitinib/*therapeutic use
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cost-Benefit Analysis ; Digestive System Neoplasms/drug therapy ; Digestive System Neoplasms/pathology ; Disease Progression ; Everolimus/adverse effects ; Everolimus/economics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Neoplasm Metastasis ; Neuroendocrine Tumors/pathology ; Octreotide/adverse effects ; Octreotide/economics ; Octreotide/therapeutic use ; Organometallic Compounds/adverse effects ; Organometallic Compounds/economics ; Quality-Adjusted Life Years ; Radioisotopes/adverse effects ; Radioisotopes/economics ; Randomized Controlled Trials as Topic ; Sunitinib/adverse effects ; Sunitinib/economics
Czasopismo naukowe
Tytuł :
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Autorzy :
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2017 Jun; Vol. 21 (38), pp. 1-294.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Treatment Outcome*
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal/*economics
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*economics
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Agents, Immunological/*economics
Cetuximab/*administration & dosage
Cetuximab/*economics
Colorectal Neoplasms/*drug therapy
Neoplasm Metastasis/*drug therapy
Cost-Benefit Analysis ; Female ; Humans ; Male ; Panitumumab ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł :
Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Autorzy :
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Coelho H; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Moore J; Exeter Kidney Unit, Royal Devon and Exeter Foundation Trust Hospital, Exeter, UK.
Allwood M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lowe J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Hyde C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Anderson R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2016 Aug; Vol. 20 (62), pp. 1-594.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Immunosuppressive Agents/*economics
Immunosuppressive Agents/*therapeutic use
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*methods
Abatacept/economics ; Abatacept/therapeutic use ; Antibodies, Monoclonal ; Antilymphocyte Serum ; Basiliximab ; Bayes Theorem ; Cost-Benefit Analysis ; Everolimus/economics ; Everolimus/therapeutic use ; Graft Rejection/prevention & control ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Models, Economic ; Mycophenolic Acid/economics ; Mycophenolic Acid/therapeutic use ; Quality of Life ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins ; Sirolimus/economics ; Sirolimus/therapeutic use ; Tacrolimus/economics ; Tacrolimus/therapeutic use ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł :
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Autorzy :
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Coelho H; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Medina-Lara A; University of Exeter Medical School, Exeter, UK.
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter Hospital, Exeter, UK.
Hyde C; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2016 Feb; Vol. 20 (13), pp. 1-588, v-vi.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms :
Cost-Benefit Analysis*
Technology Assessment, Biomedical*
Anemia/*drug therapy
Hematinics/*therapeutic use
Neoplasms/*drug therapy
Anemia/economics ; Anemia/etiology ; Hematinics/economics ; Humans ; Models, Economic ; Neoplasms/economics ; Quality-Adjusted Life Years
Czasopismo naukowe
Tytuł :
A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
Autorzy :
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Coelho H; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Frayling I; Institute of Medical Genetics, Cardiff University, Cardiff, UK.
Hyde C; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2014 Sep; Vol. 18 (58), pp. 1-406.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms :
Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis
Aged ; Colorectal Neoplasms, Hereditary Nonpolyposis/economics ; Colorectal Neoplasms, Hereditary Nonpolyposis/genetics ; Cost-Benefit Analysis ; Genetic Testing/economics ; Genetic Testing/methods ; Humans ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies